Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2026)

Protagonist Therapeutics has disclosed FCF Margin across 10 years of filings, most recently posting 87.21% for Q1 2026.

• FCF Margin for Q1 2026 came in at 87.21%, down 52974.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 159.87% (down 32588.0% YoY), and the FY2025 annual result was 121.87%, up 7980.0% from the prior year.
• FCF Margin came in at 87.21% for Q1 2026 at Protagonist Therapeutics, up from 518.45% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 166868.42% in Q4 2022 to a low of 1621.07% in Q2 2022.
• The 5-year median for FCF Margin is 18.31% (2024), against an average of 13105.05%.
• Across the five-year window, FCF Margin surged 16718243 bps in 2022 and tumbled 16669901 bps in 2023, its largest moves.
• Protagonist Therapeutics' FCF Margin stood at 166868.42% in 2022, then sank by 100 bps to 169.41% in 2023, then tumbled by 111 bps to 18.31% in 2024, then plunged by 2732 bps to 518.45% in 2025, then soared by 83 bps to 87.21% in 2026.
• The last three FCF Margin figures came in at 87.21% (Q1 2026), 518.45% (Q4 2025), and 12.46% (Q3 2025), per Business Quant data.